CLDN1 silencing increased their sensitivity to oxaliplatin, indicating that CLDN1 overexpression enhances drug resistance and highlighting its role in the acquired chemoresistance of CRC cells. The gene discussed is CLDN1; the disease is colorectal carcinoma.